In short
Clinical trials are investigating Lt3001 in people with acute ischemic stroke. The main goal is to check safety and whether the study treatment may help, compared with placebo. The available trial is a Phase 2 study in adults with this condition.
Key points
- Clinical trials of Lt3001 are studying people with acute ischemic stroke, a stroke caused by a blocked blood vessel in the brain. The main trial listed is a Phase 2 study called BRIGHT. It compares multiple doses of Lt3001 with placebo in a double-blind, randomized design. The study focuses on safety and early efficacy, with the main outcome being treatment-related adverse events within 90 days after the first dose. The trial is completed and planned to enroll 200 subjects.
Trial overview
The available study of Lt3001 is BRIGHT, a Phase 2 trial in people with acute ischemic stroke (AIS). It is a double-blind, randomized, placebo-controlled study designed to evaluate the safety and efficacy of multiple doses of Lt3001 drug product. The trial is completed and planned to enroll 200 subjects.
Study design and treatment groups
This is an interventional study, which means researchers gave a study treatment and then measured the results. Participants were assigned to either placebo or Lt3001 drug product by chance, which helps make the comparison fair. The Lt3001 group received 0.1 mg/kg by intravenous infusion, meaning the treatment was given through a vein.
Who can participate
The trial data show that the study was for subjects with acute ischemic stroke. No more detailed entry rules are provided in the source data, so the exact age range, timing rules, or other eligibility limits are not listed here.
What the trial measures
The main outcome was the proportion of subjects with adverse events judged to be probably or definitely related to the investigational product within 90 days after the first dose. In simple terms, the researchers wanted to know how many people had unwanted medical problems that seemed linked to the study treatment. The brief study summary also says the trial was done to determine the safety of multiple doses of Lt3001 in subjects with AIS.
What the results may mean
Because this is a Phase 2 trial, the study is mainly about learning more about safety and looking for early signs of benefit rather than proving final effectiveness. The placebo comparison helps researchers judge whether events seen in the Lt3001 group may be different from what happens without the active study treatment. For patients and families, the key point is that this trial focused on people with a serious stroke condition and aimed to understand whether Lt3001 could be studied further in this setting.